As a direct consequence of insider trading, the share price of Castle Biosciences, Inc. (NASDAQ: CSTL), which traded on Thursday, fell by 4.3%. At any given time, the price of one share of the company’s stock can range between $27.92 and $27.92. There were 1,184 shares transacted in the middle of the trading day, which is 99% less than the daily average volume of 174,001 shares transacted. Before that, the price of one share had reached $29.16 by the time the market closed for the day. On Monday, October 3, director Daniel Bradbury sold 7,704 shares of the company’s stock. The transaction took place on that day. The shares were acquired for a total cost of $209,317.68, which works out to a price of $27.17 per share on an average basis. After the completion of the sale, the director now has 222,651 shares in the company. When added together, the value of these shares comes to a total of $6,049,427.67. If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed. You can simply ignore this link if you do not want to follow it. Daniel Bradbury, a director of the company, sold 7,704 shares of the company’s stock on Monday, October 3. The shares were acquired for a total cost of $209,317.68, which works out to a price of $27.17 per share on an average basis. After the completion of the sale, the director now has 222,651 shares in the company. When added together, the value of these shares comes to a total of $6,049,427.67. If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed.
You can simply ignore this link if you do not want to follow it. Derek J. Maetzold, an employee of the company, sold 4,118 shares of the company’s stock on Monday, August 29. $121,728.08 was spent on purchasing the shares, totaling an average price of $29.56 per share. Following the completion of the transaction, the corporate insider will have a total of 312,414 shares of the company, which at the moment have a value of approximately $9,234,957.84. Disclosures that are related to the sale might be found in this section of the website. Business insiders were responsible for the sale of 28,509 shares of company stock at a total price of $788,138 during the most recent fiscal period. Company insiders hold the total number of shares in the company at a rate of 7.30 percent.
On August 8, Castle Biosciences (NASDAQ: CSTL) released its most recent quarterly earnings report. The company announced earnings of $0.06 per share (EPS) for the quarter, which was $0.52 better than the average estimate of $0.58 per share. The actual revenue for the quarter was $34.84 million, which was significantly higher than the average projection of $28.40 million for the revenue generated during the quarter. The return on equity and the net margin at Castle Biosciences were red. The return on equity was -9.81%, and the net margin was -40.37%. The business incurred a loss equivalent to $0.34 per share in the same period as the previous year. The majority opinion of financial market analysts is that Castle Biosciences, Inc. will report a loss of -2.81 cents in earnings per share for the current financial year.
The company’s market capitalization is currently at $734.30 million, and its beta value is 1.15. The company has a price-to-earnings ratio of -16.66. The stock price has a simple moving average of fifty days at $29.03, and its price has a simple moving average of two hundred days at $26.81.
As a result of recent occurrences, several analysts have begun to concentrate their attention on CSTL shares. The price target that SVB Leerink has set for Castle Biosciences has increased from $45.00 to $50.00 due to a research report published on Tuesday, August 9. Additionally, the company was given a rating of “market outperform” by the consulting firm. In a research note published on Monday, August 15, BTIG Research raised the price objective on shares of Castle Biosciences from its previous level of $45.00 to $47.00 in a research note. In a research report that was made public on Tuesday, August 9, Baird increased their price objective on Castle Biosciences from $44.00 to $48.00 and rated the company as having an “outperform” rating in a research report that was There had been five separate analyses that have concluded that investors should buy the stock. The company’s stock has been given a “Buy” rating on average, and analysts have agreed upon a price target of $58.86 for the stock as the consensus price target. This data was collected from the website Bloomberg.com.
Over the most recent few months, there has been a shift in the percentage of hedge funds and other institutional investors’ holdings in the company’s stock. New investment for $57,000 was made in Castle Biosciences during the first three months of the year by Lazard Asset Management LLC. In addition, Amalgamated Bank increased its holdings in Castle Biosciences by purchasing additional shares during the year’s first quarter. As a result, the bank’s total interest in the company has increased to approximately $152,000. PNC Financial Services Group Inc. grew its holdings in Castle Biosciences by 52.5% over the first three months of 2018. PNC Financial Services Group Inc. is now the proud owner of 1,290 additional shares in the company, bringing its total number of shares to 3,745, which are currently valued at $168,000.00. This is an increase from where it stood three months ago. During the second quarter of the fiscal year, the value of Captrust Financial Advisors’ holdings in Castle Biosciences increased by 762.2 percent. Captrust Financial Advisors increased their overall share count to 4,018 during the most recent quarter by purchasing an additional 3,552 shares of company stock. There is a value of $88,000 associated with these shares. During the first three months of 2018, First Bank & Trust increased the proportion of Castle Biosciences stock owned by 21.7%. The most recent fiscal quarter saw First Bank & Trust acquire an additional 733 shares of the company’s stock. This brings the total number of shares the financial institution has acquired to 4,110, with a value of $184,000.00 per share. Institutional investors, which include banks, pension funds, and insurance companies, own 86.08 percent of the company’s shares.
Most of Castle Biosciences, Inc.’s efforts are concentrated on providing diagnostic and prognostic testing services for dermatological cancer. The company is currently in the commercial stage of its development as a diagnostics provider. The business’s primary offering is called DecisionDx-Melanoma, and it is a multi-gene expression profile (GEP) test. This test is given to people with invasive cutaneous melanoma to determine how likely cancer will spread to other body parts.